MedTrace Logo

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

NCT01399190 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2016-09-28

Study results available
· View outcomes & findings →

Summary

This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer. Data will be collected from each participant until disease progression occurs (for up to 30 months).

Conditions

Interventions

BIOLOGICAL

Bevacizumab

Bevacizumab administered according to prescribing information and normal clinical practice.

BIOLOGICAL

Capecitabine

Capecitabine administered according to prescribing information and normal clinical practice.

DRUG

Oxaliplatin

Capecitabine administered according to prescribing information and normal clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01399190 on ClinicalTrials.gov